R&D Drug candidates for the treatment of neurodegeneration
Not updated yet!
ALZPROTECT is headquartered at the Eurasanté Park in Lille, France with a staff of 10 people mainly in R&D. The Company is currently engaged in discovering, developing and manufacturing innovative therapeutics to addressing orphan and major neuronal-death related pathologies mainly focusing its efforts on tauopathies such as frontotemporal degeneration / dementia (FTD), progressive supranuclear palsy (PSP) and expanding later to Alzheimer disease (AD). The Company has also identified the potential to extend its therapeutic drugs to other neurodegenerative conditions including Parkinson’s disease (PD), Huntington’s disease (HD) and Amyotrophic lateral sclerosis (ALS). The Company has tailored a portfolio of innovative small molecule drug candidates with novel and multiple mechanisms of actions to targeting pathological misfolded proteins using its proprietary technological platform and unique expertise in animal models of dementia and AD. Its main lead compound, AZP2006 has achieved clinical phase 1 and has obtained the orphan status for the treatment of PSP.